Efficacy and Safety for Rituximab Combined With Telitacicept in the Treatment of ANCA-associated Vasculitis (TTCAAVREM)
For patients and families
In plain language
An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.
- What is being studied
- The protocol lists: Telitacicept, Placebo of Telitacicept.
- Who it may be relevant to
- Registry conditions: ANCA Associated Vasculitis. Basic parameters: 18 years — 65 years · All.
- What needs checking
- Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
- Where it takes place
- China
- Next step
- Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Unsure about the terms? Read our patient guide →
Official title
A Prospective, Randomized, Single-blinded Placebo-controlled, Single Center Clinical Study of the Efficacy and Safety for Rituximab Combined With Telitacicept in the Treatment of ANCA-associated Vasculitis
Overview
This study is a prospective, open-labelled, randomized, controlled, single-center clinical trial. The aim of this study is to investigate the remission rate of patients treated with Telitacicept combined with Rituximab in remission-induction and Telitacicept alone in remission-maintain treatment.
Detailed description
Background: The basic theme of AAV is relapse and remission. The maintenance therapy of AAV aimed to reduce or prevent relapse is very challenge. Although many medications have been used for the maintenance of AAV, Telitacicept (a BAFF/APRIL dual-target-inhibitor, which has been proved to be effect in treatment of SLE) has not been studied yet. One study tested the efficacy of Belimumab in the maintenance therapy for AAV. When taken Rituximab as remission-induction treatment, no relapse was observed. However, the sample size of this study is small, and the Belimumab, as a BAFF inhibitor, was not been proved to have effect on APRIL.
Many experiences have been accumulated about the efficacy and safety of Telitacicept in Chinese patients with rheumatic diseases. But there is no study to show its effectiveness in the reduction of the relapse of AAV in China. In this study, we take Telitacicept as maintain treatment in AAV patients who receive Rituximab as remission-induction treatment, to verify the effectiveness of Telitacicept in maintenance therapy of AAV.
Objectives: To investigate the effectiveness of Telitacicept in reducing relapse rate by using from remission-induction treatment combined with Rituximab to maintenance treatment of AAV.
Study Design: This is a prospective, randomized, open-label, control, pilot study.
Interventions
- Drug Telitacicept
Patient will be treated with Telitacicept (Taiai the commercial name) 80 mg every week subcutaneously for 12 months - Other Placebo of Telitacicept
Patient will be treated with placebo of Telitacicept (Taiai the commercial name) 80 mg every week subcutaneously for 12 months
Primary outcome measures
- The time of first relapse during 24 months follow-up of two groups [Time frame: from inclusion to the end of the study, 24 months in total]
Secondary outcome measures (8)
- The time to remission of two groups [Time frame: from inclusion to the end of the study, 24 months in total]
- The time from remission to first relapse of two groups [Time frame: from inclusion to the end of the study, 24 months in total]
- The percentage of patients with sustained remission at months 12 and at months 24 of two groups [Time frame: from inclusion to the end of the study, 24 months in total]
- The percentage of patients with relapse at months 12 and at months 24 of two groups [Time frame: from inclusion to the end of the study, 24 months in total]
- The rate of adverse events and their severity in both treatment groups during 24 months of the study period. [Time frame: from inclusion to the end of the study, 24 months in total]
- The percentage of patients who progress to ESRD at the end of the study [Time frame: from inclusion to the end of the study, 24 months in total]
- The time of ANCA from positive to negative of two groups [Time frame: from inclusion to the end of the study, 24 months in total]
- The rate of complication of AAV in both treatment groups during 24 months of the study period. [Time frame: from inclusion to the end of the study, 24 months in total]
Eligibility criteria
Inclusion criteria
- Patients age 18 to 65 years, both genders can be included.
- Patients who are newly diagnosed or relapsing granulomatosis with polyangiitis or microscopic polyangiitis must fulfill the 2022 ACR/EULAR classification criteria of GPA or MPA.
- Patients have severe active AAV according to the 2021 ACR/vasculitis foundation definition.
- Patients have to be PR3-ANCA-positive at diagnosis or during the course of their disease.
Exclusion criteria
- Patients who had been treated with Rituximab but had to stop due to adverse events or intolerance.
- Patients who had other autoimmune diseases.
- Patients with severe liver dysfunction (defined as the 2-folds elevation of normal upper limit or Child grade III), heart failure or ESRD (eGFR<30ml/min).
- Patients who are pregnant or have planned for pregnancy in next 2 years.
- Patients with uncontrolled sever hypertension, diabetes, active bacteria or fungal infection.
- Patients with active hepatitis virus infection as well as patients who have active mycobacteria infection.
- Patients with malignancy.
- Patients who are not eligible according to the judge of the principal investigators.
Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.
Healthy volunteers: No
Study design
- Allocation
- Randomized
- Model
- Parallel assignment
- Masking
- Single blind
- Primary purpose
- Treatment
Study locations
China · 1 center
- Peking Union Medical College Hospital — Beijing
Identifiers
NCT: NCT05962840 · CSTAR-K2956